Press Release: Dupixent® demonstrates potential to become ... - Sanofi
Mar 23, 2006 · In this landmark Phase 3 trial, patients with uncontrolled COPD achieved clinical outcomes with Dupixent at a magnitude never before seen with a biologic. These results also …
Press Release: New late-breaking data at ATS 2023 demonstrate ... - Sanofi
May 5, 2012 · 17 abstracts showcase new data for Dupixent, itepekimab and anti-IL-13/TSLP NANOBODY ® molecule in COPD and asthma; Presentations on investigational use of …
Sanofi US News
Sep 27, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression …
FDA signs off on Regeneron and Sanofi's Dupixent for COPD
Sep 27, 2024 · Regeneron and Sanofi have announced that the FDA has expanded the label of megablockbuster Dupixent to treat COPD. The approval brings the versatile drug’s count of …
Press Release: Update on FDA priority review of Dupixent for ... - Sanofi
May 31, 2005 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression …
Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
Sep 27, 2024 · Regeneron and Sanofi are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression …
FDA speeds Sanofi, Regeneron’s application for Dupixent in COPD
Feb 22, 2024 · Regeneron and Sanofi have reached another milestone as they look to add to their megablockbuster immunology drug Dupixent a new U.S. indication for uncontrolled chronic …
Sanofi pumps up Dupixent and other respiratory pipeline drugs
May 22, 2023 · Sanofi and Regeneron made waves when they presented data from a phase 3 trial that showed that blockbuster Dupixent could become the first biologic to treat chronic …
Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD …
Sep 27, 2024 · Dupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of the drug for chronic obstructive …
Sanofi-Regeneron find narrower population of former smokers for COPD ...
Jul 21, 2021 · Sanofi and Regeneron already have a COPD trial with Dupixent, a blockbuster drug that is approved for atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps.